Townsquare Capital LLC Regeneron Pharmaceuticals, Inc. Transaction History

Townsquare Capital LLC

$8.15 Billion
Q3 2024

A detailed history of Townsquare Capital LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Townsquare Capital LLC holds 6,831 shares of REGN stock, worth $5.21 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

6,831

Previous 5,401 26.48%

Holding current value

$5.21 Million

Previous $5.68 Million 26.52%

% of portfolio

0.09%

Previous 0.08%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1024.09 - $1201.76 $1.46 Million - $1.72 Million	1,430 Added 26.48%	6,831 $7.18 Million
Q2 2024 Aug 14, 2024	BUY	$883.2 - $1071.19 $537,868 - $652,354	609 Added 12.71%	5,401 $5.68 Million
Q1 2024 May 15, 2024	BUY	$902.69 - $993.35 $233,796 - $257,277	259 Added 5.71%	4,792 $4.61 Million
Q4 2023 Feb 15, 2024	SELL	$775.18 - $881.7 $1.68 Million - $1.91 Million	-2,169 Reduced 32.36%	4,533 $3.98 Million
Q3 2023 Nov 15, 2023	BUY	$692.45 - $844.37 $238,202 - $290,463	344 Added 5.41%	6,702 $5.52 Million
Q2 2023 Nov 13, 2023	BUY	$700.03 - $830.35 $1.39 Million - $1.65 Million	1,983 Added 45.33%	6,358 $4.57 Million
Q1 2023 May 11, 2023	BUY	$680.49 - $826.97 $127,251 - $154,643	187 Added 4.47%	4,375 $3.59 Million
Q4 2022 Feb 13, 2023	BUY	$705.89 - $766.39 $220,943 - $239,880	313 Added 8.08%	4,188 $3.02 Million
Q3 2022 Nov 10, 2022	BUY	$573.97 - $724.32 $151,528 - $191,220	264 Added 7.31%	3,875 $2.67 Million
Q2 2022 Aug 08, 2022	BUY	$548.35 - $738.84 $119,540 - $161,067	218 Added 6.42%	3,611 $2.14 Million
Q1 2022 Apr 28, 2022	BUY	$595.12 - $698.43 $249,355 - $292,642	419 Added 14.09%	3,393 $2.37 Million
Q4 2021 Feb 11, 2022	BUY	$543.48 - $670.97 $294,022 - $362,994	541 Added 22.24%	2,974 $1.88 Million
Q3 2021 Nov 15, 2021	BUY	$574.03 - $680.96 $329,493 - $390,871	574 Added 30.88%	2,433 $1.47 Million
Q2 2021 Aug 16, 2021	BUY	$472.8 - $558.54 $88,413 - $104,446	187 Added 11.18%	1,859 $1.08 Million
Q1 2021 May 17, 2021	SELL	$446.73 - $548.2 $9.24 Million - $11.3 Million	-20,688 Reduced 92.52%	1,672 $791,000
Q4 2020 Feb 16, 2021	BUY	$478.3 - $607.98 $1.33 Million - $1.68 Million	2,771 Added 14.15%	22,360 $10.8 Million
Q3 2020 Dec 01, 2020	BUY	$544.75 - $658.21 $971,834 - $1.17 Million	1,784 Added 10.02%	19,589 $11.4 Million
Q2 2020 Aug 17, 2020	BUY	$493.32 - $643.92 $727,647 - $949,781	1,475 Added 9.03%	17,805 $11 Million
Q1 2020 May 18, 2020	BUY	$336.18 - $494.43 $1.27 Million - $1.86 Million	3,771 Added 30.03%	16,330 $8.58 Million
Q4 2019 May 18, 2020	BUY	$274.13 - $376.51 $58,937 - $80,949	215 Added 1.74%	12,559 $4.72 Million
Q3 2019 Nov 14, 2019	BUY	$273.46 - $318.39 $398,431 - $463,894	1,457 Added 13.38%	12,344 $4.03 Million
Q2 2019 Aug 15, 2019	SELL	$299.6 - $414.82 $80,592 - $111,586	-269 Reduced 2.41%	10,887 $3.32 Million
Q1 2019 May 15, 2019	BUY	$372.08 - $439.57 $547,329 - $646,607	1,471 Added 15.19%	11,156 $4.58 Million
Q4 2018 Feb 13, 2019	BUY	$335.82 - $403.04 $3.25 Million - $3.9 Million	9,685 New	9,685 $4.08 Million

Others Institutions Holding REGN

# of Institutions

1,530

Shares Held

84.1M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $81.7B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Townsquare Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Townsquare Capital LLC with notifications on news.

Account

Townsquare Capital LLC Regeneron Pharmaceuticals, Inc. Transaction History